According to international diabetes news today, the Candian Health Ministry is reviewing the diabetes drug Lantus following claims of an increased risk of cancer. Lantus, marketed by pharmaceutical company Sanofi-Aventis, is sold worldwide in great volumes.
The CHM reportedly commented: “Health Canada is informing Canadians of an ongoing safety review of the potential association between the diabetes drug Lantus ( insulin glargine ) and an increased risk of developing cancer .”
However, the Food and Drug Administration in America cast doubt on the studies. Lantus is a synthetic insulin used to control blood sugar amongst people with type 1 diabetes and people with type 2 diabetes .
At this stage, the Canadian authority is advising people with diabetes to contact their healthcare professional if they have concerns about their medication .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…